Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate due to ineffective treatments. Obesity is a recognized risk factor for PDAC. Thus, developing effective weight management strategies is essential to decrease obesity, and potentially mitigate PDAC risk. The high-fat, low-carbohydrate ketogenic diet (KD) promotes weight loss and is a promising therapeutic strategy in some cancer preclinical models by altering tumor metabolism. Purpose: The KD will disrupt cancer metabolism, promote weight loss, and delay tumor growth in obesity-associated PDAC. Methods: C57BL/6 mice were fed an obesogenic high-fat diet (HFD) for 15 weeks to induce obesity, after which were randomized to a control diet (CD), a KD, or continued in the HFD for 7 weeks. After, mice were orthotopically injected with mouse KRas G12D/Trp53−/−/PDX-1-CRE (mKPC) cells containing the firefly luciferase gene. Tumor growth was monitored using luminescence through an In Vivo Imaging System. Body weight, glucose tolerance tests, and ketone measurements were performed before, during, and at the study end. Tumors metabolomics were analyzed by Liquid Chromatography Mass Spectrometry. Results: Mice gained weight after 15 weeks of an obesogenic diet. Mice that were switched to a KD or CD lost weight compared to mice that remained on the HFD following diet intervention. Mice fed a KD maintained increased ketone concentrations and increased glucose tolerance after tumors. However, none of the dietary interventions decreased tumor growth. Tumors in mice fed a KD showed significant enrichment in metabolic processes, such as, vitamin B6 and vitamin B5 metabolism, the citrate cycle, and arginine biosynthesis compared to mice that remained on a HFD. Conclusions: Although the KD induced weight loss and altered tumor metabolism, it was insufficient to decrease tumor growth in an obesogenic PDAC mouse model. Our data identified vitamin B6 and vitamin B5 metabolism, the citrate cycle, and arginine biosynthesis as important compensatory metabolic processes induced by the KD. Understanding the availability and functions of these metabolic processes could identify mechanisms of diet interventions for obesity-associated PDAC to decrease obesity, and potentially mitigate PDAC growth. Citation Format: Ericka Velez-Bonet, Kristyn Gumpper-Fedus, Fouad Choueiry, Zhu Jiangjiang, Zobeida Cruz-Monserrate. Ketogenic diet enhanced nutrient metabolic pathways but did not inhibit tumor growth in an obesity-associated PDAC mouse model [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C052.